These results were all consistent with our previous finding that DUXAP8 was downregulated in NSCLC cells treated with Aila, indicating that downregulation of DUXAP8 may represent a potential therapeutic strategy for the treatment of NSCLC. Here, DUXAP8 is linked to non-small cell lung carcinoma.